Shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) have been assigned an average recommendation of “Hold” from the seven brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $13.33.
A number of research firms have issued reports on SGMO. ValuEngine cut W&T Offshore from a “hold” rating to a “sell” rating in a report on Friday, April 26th. Zacks Investment Research upgraded General Moly from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. Finally, Wedbush set a $11.00 price target on Sangamo Therapeutics and gave the stock a “hold” rating in a report on Monday, July 8th.
In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at approximately $305,120. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is currently owned by corporate insiders.
NASDAQ:SGMO traded down $0.31 on Tuesday, reaching $11.69. 1,233,100 shares of the stock traded hands, compared to its average volume of 2,171,707. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -16.70 and a beta of 2.99. The firm has a 50 day moving average of $10.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.98 and a quick ratio of 3.98. Sangamo Therapeutics has a 1-year low of $6.26 and a 1-year high of $19.25.
Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.14). The firm had revenue of $8.07 million for the quarter, compared to analyst estimates of $27.21 million. Sangamo Therapeutics had a negative net margin of 113.03% and a negative return on equity of 24.67%. On average, sell-side analysts predict that Sangamo Therapeutics will post -1.46 earnings per share for the current fiscal year.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Further Reading: How much money do you need to begin day trading?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.